Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 14, Issue 11, Pages 1199-1212
Publisher
Informa UK Limited
Online
2019-08-07
DOI
10.1080/17460441.2019.1646244
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2019) Mitchell T Wallin et al. LANCET NEUROLOGY
- Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis
- (2018) Yusei Miyazaki et al. CLINICAL IMMUNOLOGY
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
- (2018) Andrea Huwiler et al. PHARMACOLOGY & THERAPEUTICS
- Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
- (2018) Tanuja Chitnis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Siponimod for the treatment of secondary progressive multiple sclerosis
- (2018) Laura Dumitrescu et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
- (2018) Stefan Braune et al. JOURNAL OF NEUROLOGY
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis
- (2017) Katja Thomas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Fingolimod (Gilenya® ) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?
- (2017) Sylvie Pilote et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- The multiple sclerosis market
- (2017) Anders Westad et al. NATURE REVIEWS DRUG DISCOVERY
- Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
- (2017) Jonathan Alsop et al. PLoS One
- Classifying PML risk with disease modifying therapies
- (2017) Joseph R. Berger Multiple Sclerosis and Related Disorders
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
- (2016) Tjalf Ziemssen et al. BMC Neurology
- Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach
- (2016) Nelleke Snelder et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Fingolimod-associated PML in a patient with prior immunosuppression
- (2016) Tirisham V. Gyang et al. NEUROLOGY
- Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments
- (2016) Faik Imeri et al. NEUROPHARMACOLOGY
- Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation—Reply
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation
- (2016) Chittaranjan Andrade JAMA Neurology
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- (2015) Samuel F. Hunter et al. CNS DRUGS
- Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail
- (2015) Jeroen Van Schependom et al. Multiple Sclerosis Journal
- Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail
- (2015) Jeroen Van Schependom et al. Multiple Sclerosis Journal
- Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
- (2014) John Camm et al. AMERICAN HEART JOURNAL
- Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in Kuwait
- (2014) Jasem AL-Hashel et al. CNS DRUGS
- Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis
- (2014) Niklas Bergvall et al. CURRENT MEDICAL RESEARCH AND OPINION
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
- (2013) Marco A. Zarbin et al. OPHTHALMOLOGY
- Fingolimod-Associated Macular Edema: Resolution by Sub-Tenon Injection of Triamcinolone With Continued Fingolimod Use
- (2013) Ashley Minuk et al. JAMA Ophthalmology
- Progressive multifocal leukoencephalopathy in autoimmune diseases
- (2012) Elisabeth Palazzo et al. JOINT BONE SPINE
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis
- (2010) Alina Kułakowska et al. NEUROSCIENCE LETTERS
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
- (2010) J. W. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SphK1 Regulates Proinflammatory Responses Associated with Endotoxin and Polymicrobial Sepsis
- (2010) P. Puneet et al. SCIENCE
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
- (2009) Volker Brinkmann BRITISH JOURNAL OF PHARMACOLOGY
- Regulation of vascular physiology and pathology by the S1P2 receptor subtype
- (2009) A. Skoura et al. CARDIOVASCULAR RESEARCH
- Role of Sphingosine-1-Phosphate Phosphohydrolase 1 in the Regulation of Resistance Artery Tone
- (2008) Bernhard Friedrich Peter et al. CIRCULATION RESEARCH
- S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell Egress
- (2008) Trung H.M. Pham et al. IMMUNITY
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now